Piomic, a Zurich based MedTech start-up has successfully raised an undisclosed seed round investment with the continuing commitment of existing business angels and a pool of private investors, after receiving strong initial results from first patients enrolled in Piomic´s clinical pilot trial. Proceeds of the financing will be used to accelerate the development of its advanced wound care product, expand its team and operations and to further strengthen the clinical body of evidence supporting the effectiveness of its core technology.
Piomic develops an innovative non-invasive medical device for treatment of chronic wounds. Driven by diabetes and the effects of an over aging population, hard-to-heal wounds remain a major challenge for modern health care systems. With more than 50 million patients affected, the company wants to provide clinical and economic benefits to institutions treating non-healing wounds.
“We are pleased to have such a strong group of investors supporting our company” said Christopher Hertz, co-founder and CEO of Piomic. “The continuous positive feedback of patients and physicians is a positive endorsement of Piomic´s therapeutic approach. We believe that life shouldn't be defined by a medical condition. By developing a therapy which is safe and effective we hope to set a better future for everyone in need.”
In addition to the round, Piomic is excited to welcome Bertrand Hughes as an additional key advisor to the company. Bertrand was previously Global Business Director of the Electrical Stimulation business unit at Mölnlycke Health Care and comes with extensive experience in the advanced wound care and MedTech market.